A Phase 1 Study of the Safety and Tolerability of Intravesical Administration of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2014
At a glance
- Drugs Nadofaragene-firadenovec (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; First in man
- Sponsors Merck Sharp & Dohme
- 31 Aug 2018 Biomarkers information updated
- 09 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.